<p>Autolus Therapeutics PLC 赞助的 ADR (NASDAQ:AUTL - 获取免费报告) 的股价在周一的午盘交易中上涨了 13.5%，此前 Needham &amp; Company LLC 将该股的目标价从 10.00 美元上调至 11.00 美元。Needham &amp; Company LLC 目前对该股给予买入评级。Autolus Therapeutics 的股价最高达到 1.89 美元，最后交易价为 1.8950 美元。在午盘交易中，约有 2,745,350 股被交易，较平均每日交易量 2,479,643 股增加了 11%。该股此前收盘价为 1.67 美元。</p>
<p>获取 <strong>Autolus Therapeutics</strong> 的提醒：</p>
<p>其他几位分析师最近也对该股发表了评论。William Blair 在 9 月 24 日的研究报告中重申了对 Autolus Therapeutics 股票的 “跑赢大盘” 评级。华尔街 Zen 在 11 月 15 日的研究报告中将 Autolus Therapeutics 的股票评级从 “持有” 下调至 “强烈卖出”。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Autolus Therapeutics 股票的 “卖出（d-）” 评级。四位研究分析师对该股给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 8.67 美元。</p>
<p><strong>阅读我们关于 Autolus Therapeutics 的最新报告</strong></p>
<h2>机构投资者对 Autolus Therapeutics 的看法</h2>
<p>对该股的对冲基金最近增加或减少了持股。Marex Group plc 在第二季度购买了价值约 28,000 美元的 Autolus Therapeutics 新头寸。Caitong International Asset Management Co. Ltd 在第三季度收购了价值约 46,000 美元的 Autolus Therapeutics 新股份。R Squared Ltd 在第二季度收购了价值 50,000 美元的 Autolus Therapeutics 新股份。Invesco Ltd. 在第一季度将其在 Autolus Therapeutics 的股份增加了 53.3%。Invesco Ltd. 目前拥有该公司 32,738 股股票，价值 51,000 美元，此前在上个季度又购买了 11,381 股。最后，Delaney Dennis R 在第二季度收购了价值约 55,000 美元的 Autolus Therapeutics 新股份。72.83% 的股票目前由机构投资者持有。</p>
<h2>Autolus Therapeutics 股价上涨 12.9%</h2>
<p>该公司的市值为 5.0167 亿美元，市盈率为 -2.30，贝塔值为 2.01。该股的 50 日移动平均价格为 1.48 美元，200 日移动平均价格为 1.78 美元。</p>
<p>Autolus Therapeutics (NASDAQ:AUTL - 获取免费报告) 最近在 11 月 12 日发布了季度财报。该公司报告本季度每股收益为（0.30）美元，低于分析师共识预期的（0.23）美元，差额为（0.07）美元。该业务本季度的收入为 2,119 万美元，而分析师预期为 2,108 万美元。Autolus Therapeutics 的股本回报率为 -63.76%，净利润率为 -439.69%。平均而言，卖方分析师预测 Autolus Therapeutics PLC 赞助的 ADR 本年度将发布 -0.94 的每股收益。</p>
<h2>Autolus Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Autolus Therapeutics 是一家临床阶段的生物制药公司，专注于开发下一代程序化 T 细胞疗法以治疗癌症。该公司利用专有技术工程化自体 T 细胞，针对并消灭肿瘤细胞，旨在提高安全性、疗效和耐久性，超越现有的细胞疗法。其研发平台整合了抗原受体设计、基因编辑和制造优化，以生成针对特定血液恶性肿瘤和实体肿瘤适应症的候选药物。</p>
<p>该公司的主要管线候选药物包括 AUTO1，一种针对复发或难治性急性淋巴细胞白血病的优化 CD19 靶向 CAR-T 疗法，以及 AUTO3，一种针对弥漫性大 B 细胞淋巴瘤的双靶向 CD19/22 CAR-T 项目。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Autolus Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将腾飞</li>
<li>100 万美元在退休后能维持多久？</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Autolus Therapeutics 吗？</h2>
<p>在你考虑投资 Autolus Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Autolus Therapeutics 并不在名单上。</p>
<p>虽然 Autolus Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AUTL

<p>Autolus Therapeutics (NASDAQ:AUTL) 的股价上涨了 13.5%，因为 Needham & Company 将其目标价从 10.00 美元上调至 11.00 美元，并维持买入评级。该股票交易价格为 1.8950 美元，成交量增加了 11%。分析师的评级各不相同，四个买入评级和一个卖出评级。该公司报告的季度每股收益为 -0.30 美元，未达到预期，但收入略高于预期，达到 2119 万美元。Autolus 专注于开发用于癌症治疗的 T 细胞疗法，主要候选药物包括 AUTO1 和 AUTO3</p>

<p>Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report)'s stock price rose 13.5% during mid-day trading on Monday after Needham &amp; Company LLC raised their price target on the stock from $10.00 to $11.00. Needham &amp; Company LLC currently has a buy rating on the stock. Autolus Therapeutics traded as high as $1.89 and last traded at $1.8950. Approximately 2,745,350 shares were traded during mid-day trading, an increase of 11% from the average daily volume of 2,479,643 shares. The stock had previously closed at $1.67.</p>
<div class="lb-trans"><p>Autolus Therapeutics PLC 赞助的 ADR (NASDAQ:AUTL - 获取免费报告) 的股价在周一的午盘交易中上涨了 13.5%，此前 Needham &amp; Company LLC 将该股的目标价从 10.00 美元上调至 11.00 美元。Needham &amp; Company LLC 目前对该股给予买入评级。Autolus Therapeutics 的股价最高达到 1.89 美元，最后交易价为 1.8950 美元。在午盘交易中，约有 2,745,350 股被交易，较平均每日交易量 2,479,643 股增加了 11%。该股此前收盘价为 1.67 美元。</p>
</div><p>Get <strong>Autolus Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Autolus Therapeutics</strong> 的提醒：</p>
</div><p>Several other analysts have also recently commented on the stock. William Blair reiterated an &#34;outperform&#34; rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Wall Street Zen downgraded shares of Autolus Therapeutics from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $8.67.</p>
<div class="lb-trans"><p>其他几位分析师最近也对该股发表了评论。William Blair 在 9 月 24 日的研究报告中重申了对 Autolus Therapeutics 股票的 “跑赢大盘” 评级。华尔街 Zen 在 11 月 15 日的研究报告中将 Autolus Therapeutics 的股票评级从 “持有” 下调至 “强烈卖出”。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Autolus Therapeutics 股票的 “卖出（d-）” 评级。四位研究分析师对该股给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 8.67 美元。</p>
</div><p><strong>Read Our Latest Report on Autolus Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Autolus Therapeutics 的最新报告</strong></p>
</div><h2>Institutional Investors Weigh In On Autolus Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Autolus Therapeutics 的看法</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the stock. Marex Group plc bought a new position in Autolus Therapeutics during the second quarter valued at about $28,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Autolus Therapeutics during the third quarter worth approximately $46,000. R Squared Ltd acquired a new position in shares of Autolus Therapeutics in the second quarter worth $50,000. Invesco Ltd. raised its stake in shares of Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after purchasing an additional 11,381 shares in the last quarter. Finally, Delaney Dennis R acquired a new stake in Autolus Therapeutics in the second quarter valued at approximately $55,000. 72.83% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对该股的对冲基金最近增加或减少了持股。Marex Group plc 在第二季度购买了价值约 28,000 美元的 Autolus Therapeutics 新头寸。Caitong International Asset Management Co. Ltd 在第三季度收购了价值约 46,000 美元的 Autolus Therapeutics 新股份。R Squared Ltd 在第二季度收购了价值 50,000 美元的 Autolus Therapeutics 新股份。Invesco Ltd. 在第一季度将其在 Autolus Therapeutics 的股份增加了 53.3%。Invesco Ltd. 目前拥有该公司 32,738 股股票，价值 51,000 美元，此前在上个季度又购买了 11,381 股。最后，Delaney Dennis R 在第二季度收购了价值约 55,000 美元的 Autolus Therapeutics 新股份。72.83% 的股票目前由机构投资者持有。</p>
</div><h2>Autolus Therapeutics Trading Up 12.9%</h2>
<div class="lb-trans"><h2>Autolus Therapeutics 股价上涨 12.9%</h2>
</div><p>The firm has a market cap of $501.67 million, a price-to-earnings ratio of -2.30 and a beta of 2.01. The stock has a fifty day moving average price of $1.48 and a 200 day moving average price of $1.78.</p>
<div class="lb-trans"><p>该公司的市值为 5.0167 亿美元，市盈率为 -2.30，贝塔值为 2.01。该股的 50 日移动平均价格为 1.48 美元，200 日移动平均价格为 1.78 美元。</p>
</div><p>Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.07). The business had revenue of $21.19 million for the quarter, compared to analyst estimates of $21.08 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. On average, sell-side analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.</p>
<div class="lb-trans"><p>Autolus Therapeutics (NASDAQ:AUTL - 获取免费报告) 最近在 11 月 12 日发布了季度财报。该公司报告本季度每股收益为（0.30）美元，低于分析师共识预期的（0.23）美元，差额为（0.07）美元。该业务本季度的收入为 2,119 万美元，而分析师预期为 2,108 万美元。Autolus Therapeutics 的股本回报率为 -63.76%，净利润率为 -439.69%。平均而言，卖方分析师预测 Autolus Therapeutics PLC 赞助的 ADR 本年度将发布 -0.94 的每股收益。</p>
</div><h2>Autolus Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Autolus Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&amp;D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.</p>
<div class="lb-trans"><p>Autolus Therapeutics 是一家临床阶段的生物制药公司，专注于开发下一代程序化 T 细胞疗法以治疗癌症。该公司利用专有技术工程化自体 T 细胞，针对并消灭肿瘤细胞，旨在提高安全性、疗效和耐久性，超越现有的细胞疗法。其研发平台整合了抗原受体设计、基因编辑和制造优化，以生成针对特定血液恶性肿瘤和实体肿瘤适应症的候选药物。</p>
</div><p>The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.</p>
<div class="lb-trans"><p>该公司的主要管线候选药物包括 AUTO1，一种针对复发或难治性急性淋巴细胞白血病的优化 CD19 靶向 CAR-T 疗法，以及 AUTO3，一种针对弥漫性大 B 细胞淋巴瘤的双靶向 CD19/22 CAR-T 项目。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Autolus Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>How the Rich Retire</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Autolus Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将腾飞</li>
<li>100 万美元在退休后能维持多久？</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Autolus Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Autolus Therapeutics 吗？</h2>
</div><p>Before you consider Autolus Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Autolus Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Autolus Therapeutics 并不在名单上。</p>
</div><p>While Autolus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Autolus Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Autolus Therapeutics（NASDAQ:AUTL）股价因分析师上调评级而上涨 13.5%